Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 157

Results For "treatment"

3735 News Found

Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer
Clinical Trials | January 13, 2025

Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer

If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population


Steven R. Smith joins Zealand Pharma as Senior Global Medical Advisor in Obesity
People | January 13, 2025

Steven R. Smith joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications


Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
Clinical Trials | January 13, 2025

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure


Iconovo and Lonza to collaborate on formulation development of an intranasal biologic
News | January 13, 2025

Iconovo and Lonza to collaborate on formulation development of an intranasal biologic

Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)


ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
News | January 10, 2025

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe

According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually


Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
Clinical Trials | January 10, 2025

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients


Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
News | January 09, 2025

Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav

Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors


JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
News | January 09, 2025

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)


Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
News | January 09, 2025

Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion


1.48 lakh new TB cases identified in the first 30 days of TB Mukt Bharat -100 Days Intensified Campaign
Policy | January 07, 2025

1.48 lakh new TB cases identified in the first 30 days of TB Mukt Bharat -100 Days Intensified Campaign

Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign